Preclinical Studies Comparing Efficacy and Toxicity of DNA Repair Inhibitors, Olaparib, and AsiDNA, in the Treatment of Carboplatin-Resistant Tumors

Purpose: Carboplatin is used to treat many cancers, but occurrence of drug resistance and its high toxicity remain a clinical hurdle limiting its efficacy. We compared the efficacy and toxicity of DNA repair inhibitors olaparib or AsiDNA administered alone or in combination with carboplatin. Olapari...

Descripción completa

Detalles Bibliográficos
Autores principales: Herath, Nirmitha I., Berthault, Nathalie, Thierry, Sylvain, Jdey, Wael, Lienafa, Marie-Christine, Bono, Françoise, Noguiez-Hellin, Patricia, Sun, Jian-Sheng, Dutreix, Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861330/
https://www.ncbi.nlm.nih.gov/pubmed/31781480
http://dx.doi.org/10.3389/fonc.2019.01097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861330/
https://www.ncbi.nlm.nih.gov/pubmed/31781480
http://dx.doi.org/10.3389/fonc.2019.01097

Ejemplares similares